Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
27
ABUS Quote, Financials, Valuation and Earnings
Last price:
$3.20
Seasonality move
:
21.65%
Day range:
$3.16 - $3.26
52-week range:
$2.21 - $4.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
85.85x
P/B ratio:
5.69x
Volume:
3M
Avg. volume:
922.9K
1-year change:
45.25%
Market cap:
$608.3M
Revenue:
$18.1M
EPS (TTM):
-$0.43
Analysts' Opinion
-
Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Arbutus Biopharma has an estimated upside of 62.39% from its current price of $3.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.21.
Fair Value
-
According to the consensus of 0 analysts, Arbutus Biopharma has 62.39% upside to fair value with a price target of -- per share.
ABUS vs. S&P 500
-
Over the past 5 trading days, Arbutus Biopharma has underperformed the S&P 500 by -5.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Arbutus Biopharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arbutus Biopharma revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Arbutus Biopharma reported revenues of $1.3M.
Earnings Growth
-
Arbutus Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arbutus Biopharma reported earnings per share of -$0.10.
Enterprise value:
480.5M
EV / Invested capital:
4.50x
Price / LTM sales:
85.85x
EV / EBIT:
--
EV / Revenue:
71.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.68x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-50.88%
Net Income Margin (TTM):
-1137.65%
Return On Equity:
-67.36%
Return On Invested Capital:
-67.36%
Operating Margin:
-1304.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $36M | $22.2M | $6.7M | $4.7M | $1.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$62.9M | -$78.5M | -$78.5M | -$21.4M | -$17.5M | |
| EBITDA | -$60.9M | -$73.4M | -$75.1M | -$19.7M | -$19.4M | |
| Diluted EPS | -$0.48 | -$0.46 | -$0.43 | -$0.12 | -$0.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $121.2M | $126.5M | $141.1M | $141.6M | $132.8M | |
| Total Assets | $131.1M | $165.6M | $203.8M | $158.6M | $140.4M | |
| Current Liabilities | $7.6M | $10.1M | $27.5M | $22.3M | $18.9M | |
| Total Liabilities | $33.8M | $35.5M | $58.3M | $39.3M | $33.6M | |
| Total Equity | $97.3M | $130.1M | $145.5M | $119.3M | $106.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$38M | -$85.6M | -$71.8M | -$21.8M | -$20.7M | |
| Cash From Investing | -$95.7M | $41.2M | $31.8M | $10.4M | -$12M | |
| Cash From Financing | $79.9M | $37.9M | $54.4M | $1.7M | $1.8M | |
| Free Cash Flow | -$38.4M | -$86.8M | -$71.9M | -$21.8M | -$20.7M | |
ABUS
Sector
Market Cap
$608.3M
$44.6M
Price % of 52-Week High
67.94%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-6.58%
-0.68%
1-Year Price Total Return
45.25%
-29.09%
Beta (5-Year)
1.842
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.41
200-day SMA
Sell
Level
$3.44
Bollinger Bands (100)
Sell
Level
3.53 - 4.11
Chaikin Money Flow
Sell
Level
-496.5M
20-day SMA
Sell
Level
$3.50
Relative Strength Index (RSI14)
Sell
Level
33.79
ADX Line
Neutral
Level
Williams %R
Buy
Level
-87.8788
50-day SMA
Sell
Level
$3.71
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
328.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.3574)
Sell
CA Score
(Annual)
Level (-1.3588)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.3748)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Stock Forecast FAQ
In the current month, ABUS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ABUS average analyst price target in the past 3 months is --.
-
Where Will Arbutus Biopharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arbutus Biopharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Arbutus Biopharma?
Analysts are divided on their view about Arbutus Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arbutus Biopharma is a Sell and believe this share price will drop from its current level to --.
-
What Is Arbutus Biopharma's Price Target?
The price target for Arbutus Biopharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ABUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arbutus Biopharma is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABUS?
You can purchase shares of Arbutus Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arbutus Biopharma shares.
-
What Is The Arbutus Biopharma Share Price Today?
Arbutus Biopharma was last trading at $3.20 per share. This represents the most recent stock quote for Arbutus Biopharma. Yesterday, Arbutus Biopharma closed at $3.21 per share.
-
How To Buy Arbutus Biopharma Stock Online?
In order to purchase Arbutus Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
